Literature DB >> 8985421

Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

D Hazuda1, P Felock, J Hastings, B Pramanik, A Wolfe, G Goodarzi, A Vora, K Brackmann, D Grandgenett.   

Abstract

In vitro assay systems which use recombinant retroviral integrase (IN) and short DNA oligonucleotides fail to recapitulate the full-site integration reaction as it is known to occur in vivo. The relevance of using such circumscribed in vitro assays to define inhibitors of retroviral integration has not been formerly demonstrated. Therefore, we analyzed a series of structurally diverse inhibitors with respect to inhibition of both half-site and full-site strand transfer reactions with either recombinant or virion-produced IN. Half-site and full-site reactions catalyzed by avian myeloblastosis virus and human immunodeficiency virus type 1 (HIV-1) IN from virions are shown to be equivalently sensitive to inhibition by compounds which inhibit half-site reactions catalyzed by the recombinant HIV-1 IN. These studies therefore support the utility of using in vitro assays employing either recombinant or virion-derived IN to identify inhibitors of integration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985421      PMCID: PMC191122     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity.

Authors:  D P Grandgenett; A C Vora; R D Schiff
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

2.  HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer.

Authors:  A Engelman; K Mizuuchi; R Craigie
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

3.  Relationship of avian retrovirus DNA synthesis to integration in vitro.

Authors:  Y M Lee; J M Coffin
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

4.  Defining nucleic acid-binding properties of avian retrovirus integrase by deletion analysis.

Authors:  S R Mumm; D P Grandgenett
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

5.  The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.

Authors:  R A Katz; G Merkel; J Kulkosky; J Leis; A M Skalka
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

6.  Correct integration of retroviral DNA in vitro.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

7.  Integration of human immunodeficiency virus type 1 DNA in vitro.

Authors:  C M Farnet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

8.  Retroviral DNA integration directed by HIV integration protein in vitro.

Authors:  F D Bushman; T Fujiwara; R Craigie
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

9.  Human immunodeficiency virus integration in a cell-free system.

Authors:  V Ellison; H Abrams; T Roe; J Lifson; P Brown
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

10.  Retroviral DNA integration: structure of an integration intermediate.

Authors:  T Fujiwara; K Mizuuchi
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

View more
  7 in total

1.  Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor.

Authors:  J Lubkowski; F Yang; J Alexandratos; A Wlodawer; H Zhao; T R Burke; N Neamati; Y Pommier; G Merkel; A M Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  Effects of mutations in residues near the active site of human immunodeficiency virus type 1 integrase on specific enzyme-substrate interactions.

Authors:  J L Gerton; S Ohgi; M Olsen; J DeRisi; P O Brown
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.

Authors:  N Vandegraaff; R Kumar; H Hocking; T R Burke; J Mills; D Rhodes; C J Burrell; P Li
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.

Authors:  D J Hazuda; P J Felock; J C Hastings; B Pramanik; A L Wolfe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  Retroviral integrase: Structure, mechanism, and inhibition.

Authors:  Dario Oliveira Passos; Min Li; Robert Craigie; Dmitry Lyumkis
Journal:  Enzymes       Date:  2021-08-23

6.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 7.  Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.

Authors:  Steven J Smith; Xue Zhi Zhao; Dario Oliveira Passos; Dmitry Lyumkis; Terrence R Burke; Stephen H Hughes
Journal:  Viruses       Date:  2021-01-29       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.